<DOC>
	<DOCNO>NCT01370148</DOCNO>
	<brief_summary>The purpose study ass pharmacokinetics safety 48-hour continuous infusion conivaptan subject severe liver impairment compare subject normal liver function .</brief_summary>
	<brief_title>A Study Assess Effect Severe Hepatic Impairment Pharmacokinetics Intravenous Conivaptan</brief_title>
	<detailed_description>Subjects admit Phase 1 unit Day -2 remain confined unit discharge Study Day 5 completion study procedure .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Conivaptan</mesh_term>
	<criteria>Subjects Normal Hepatic Function : Female subject must either : postmenopausal prior Screening , premenarchal prior Screening , document surgically sterile post hysterectomy , childbearing potential , must negative pregnancy test Screening must use highly effective contraception prior Screening throughout study period 28 day final study drug administration Female subject must lactate must breastfeed Screening study period , 28 day final study drug administration Female subject must donate ovum start Screening study period , 28 day final study drug administration Male subject must : use highly effective contraception consist two form birth control ( one must barrier method ) start Screening continue throughout study period , 28 day final study drug administration donate sperm start Screening throughout study period , least 28 day final study drug administration Subject weigh least 45 kg body mass index 18 40 kg/m2 inclusive The subject must clinical laboratory test result within normal range , include liver function test ( LFTs ) The subject must normal 12lead electrocardiogram ( ECG ) Hepatic Impaired Subjects : Female subject must either : postmenopausal prior Screening , premenarchal prior Screening , document surgically sterile post hysterectomy , childbearing potential , must negative pregnancy test Screening must use highly effective contraception prior Screening throughout study period 28 day final study drug administration Female subject must lactate must breastfeed Screening study period , 28 day final study drug administration Female subject must donate ovum start Screening study period , 28 day final study drug administration Male subject must : use highly effective contraception consist two form birth control ( one must barrier method ) start Screening continue throughout study period , 28 day final study drug administration donate sperm start Screening throughout study period , least 28 day final study drug administration Subject meet criterion severe hepatic impairment define ChildPugh method Subject weigh least 45 kg body mass index 18 40 kg/m2 inclusive The subject must clinical laboratory test result within therapeutic range except hepatic disease The subject must normal 12lead electrocardiogram ( ECG ) Subjects Normal Hepatic Function : Subject history clinically significant illness , associate clinical symptom , medical condition , laboratory abnormality within past 3 month would preclude participation study Subject evidence biliary obstruction cause hepatic impairment Subject know hepatitis carrier hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibody , know HIV positive HIV antibody Subject impair ability sense thirst Subject serum sodium le 115mEg/L great 140 mEg/L Subject either systolic blood pressure ( BP ) great 140 mmHg diastolic BP le 56 mmHg Subject take prescription overthecounter medication except contraceptive , hormone replacement therapy occasional acetaminophen , alternative complementary medicine within past 14 day Subject history carcinoma , except basal cell cutaneous squamous cell carcinoma within past 5 year Subject drink great 14 unit alcohol per week ( Note : one unit = 12 ounce beer , 4 ounce wine , 1 ounce spirit ) Subject history substance abuse within past 6 month prior Screening Visit subject test positive Screening clinic admission alcohol drug abuse Subject currently participate another clinical trial receive investigational medication within past 30 day Subject know hypersensitivity conivaptan derivative Subject blood transfusion donated/lost 550ml blood within past 8 week Subject incapable compliant protocol Subjects Hepatic Impairment : Subject history clinically significant illness , associate clinical symptom , medical condition , laboratory abnormality within past 3 month would preclude participation study . Subjects control hypertension may allow Subject condition associate hepatic disease include ; biliary obstruction , cause hepatic impairment relate parenchymal disorder and/or disease liver , fluctuate rapidly deteriorate hepatic function , biliary liver cirrhosis , history presence hepatic encephalopathy great Grade 1 within past 3 month unstable encephalopathy prior Screening , tense ascites , esophageal/gastric variceal bleed past 6 month , server portal hypertension , surgical portal systemic shunt peritoneal venous shunt , thrombocyte level 50,000 x 10^9/L prothrombin time ( PT ) 18 second Subject hypovolemic evidence orthostatic hypotension Subject impair ability sense thirst Subject serum sodium le 115mEg/L great 140 mEg/L Subject either systolic blood pressure ( BP ) great 140 mmHg diastolic BP le 56 mmHg Subject know HIV positive HIV antibody Subject change dose regimen medication need underlying medical condition past four week Subject currently take prohibit medication Subject drink great 14 unit alcohol per week ( Note : one unit equal 12 ounce beer , 4 ounce wine , 1 ounce spirit ) Subject history substance abuse within past 6 month prior Screening Visit subject test positive Screening clinic admission alcohol drug abuse Subject currently participate another clinical trial receive investigational medication past 30 day Subject blood transfusion donated/lost 550ml blood within past 8 week Subject know hypersensitivity conivaptan derivative Subject incapable compliant protocol</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Protein Binding</keyword>
	<keyword>Conivaptan</keyword>
	<keyword>Vaprisol</keyword>
	<keyword>Liver Disease</keyword>
	<keyword>YM087</keyword>
</DOC>